Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

749
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
749
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.5K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

654
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

614
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
614

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel 3D Bioprinting Strategy for Bioengineering of Urethra with Clinical Relevance.

Tissue engineering. Part A·2026
Same author

Does a 24-h closed-suction drain reduce infection and hematoma after inflatable penile prosthesis surgery? A comparative study.

The journal of sexual medicine·2026
Same author

Revolutionizing Male Infertility Care: Emerging Technologies and Future Clinical Directions.

The world journal of men's health·2026
Same author

A first-in-human pilot study of Wharton's jelly-derived mesenchymal stem cell injection for urethral stricture: safety and preliminary efficacy.

World journal of urology·2026
Same author

Management of Non-Obstructive Azoospermia: Practical Answers to Key Clinical Questions.

The world journal of men's health·2026
Same author

Impact of Online Surgical Videos on Urological Practice from Screen to Surgery: A Comparative Analysis of Video Selection Criteria and Practice Modification among Urologists.

Urologia internationalis·2026

Related Experiment Video

Updated: Apr 7, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

4.0K

Tadalafil therapy for erectile dysfunction following prostatectomy.

Ateş Kadıoğlu1, Mazhar Ortaç1, Murat Dinçer1

  • 1Department of Urology, Istanbul Faculty of Medicine, Istanbul, Turkey.

Therapeutic Advances in Urology
|July 11, 2015
PubMed
Summary

Early penile rehabilitation with tadalafil, a phosphodiesterase type 5 (PDE-5) inhibitor, may improve erectile function after radical prostatectomy. This review analyzes tadalafil

Keywords:
erectile dysfunctionpenile rehabilitationradical prostatectomytadalafil

More Related Videos

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

2.0K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.3K

Related Experiment Videos

Last Updated: Apr 7, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

4.0K
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

2.0K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.3K

Area of Science:

  • Urology
  • Andrology
  • Pharmacology

Background:

  • Radical prostatectomy frequently leads to erectile dysfunction, impacting patient quality of life.
  • Penile rehabilitation is crucial for restoring erectile function post-surgery.
  • Phosphodiesterase type 5 (PDE-5) inhibitors are a primary treatment for erectile dysfunction.

Purpose of the Study:

  • To evaluate the literature on tadalafil's efficacy in penile rehabilitation after radical prostatectomy.
  • To analyze the impact of tadalafil on erectile function recovery post-surgery.

Main Methods:

  • Literature review of studies on tadalafil for erectile dysfunction.
  • Critical analysis of existing evidence regarding tadalafil's role in post-prostatectomy penile rehabilitation.

Main Results:

  • Tadalafil, a long-acting PDE-5 inhibitor, shows promise in preclinical studies for preserving penile tissue.
  • Evidence suggests tadalafil may be effective in improving erectile function following radical prostatectomy.

Conclusions:

  • Tadalafil is a potential first-line option for penile rehabilitation post-radical prostatectomy.
  • Further clinical evaluation is warranted to confirm tadalafil's long-term benefits in this patient population.